Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Evaldas Katilius.
PLOS ONE | 2010
Larry Gold; Deborah Ayers; Jennifer Bertino; Christopher Bock; Ashley Bock; Edward N. Brody; Jeff Carter; Andrew Dalby; Bruce E. Eaton; Tim Fitzwater; Dylan Flather; Ashley Forbes; Trudi Foreman; Cate Fowler; Bharat Gawande; Meredith Goss; Magda Gunn; Shashi Kumar Gupta; Dennis Halladay; Jim Heil; Joe Heilig; Brian Hicke; Gregory M. Husar; Nebojsa Janjic; Thale Jarvis; Susan Jennings; Evaldas Katilius; Tracy R. Keeney; Nancy D. Kim; Tad H. Koch
BACKGROUNDnThe interrogation of proteomes (proteomics) in a highly multiplexed and efficient manner remains a coveted and challenging goal in biology and medicine.nnnMETHODOLOGY/PRINCIPAL FINDINGSnWe present a new aptamer-based proteomic technology for biomarker discovery capable of simultaneously measuring thousands of proteins from small sample volumes (15 µL of serum or plasma). Our current assay measures 813 proteins with low limits of detection (1 pM median), 7 logs of overall dynamic range (~100 fM-1 µM), and 5% median coefficient of variation. This technology is enabled by a new generation of aptamers that contain chemically modified nucleotides, which greatly expand the physicochemical diversity of the large randomized nucleic acid libraries from which the aptamers are selected. Proteins in complex matrices such as plasma are measured with a process that transforms a signature of protein concentrations into a corresponding signature of DNA aptamer concentrations, which is quantified on a DNA microarray. Our assay takes advantage of the dual nature of aptamers as both folded protein-binding entities with defined shapes and unique nucleotide sequences recognizable by specific hybridization probes. To demonstrate the utility of our proteomics biomarker discovery technology, we applied it to a clinical study of chronic kidney disease (CKD). We identified two well known CKD biomarkers as well as an additional 58 potential CKD biomarkers. These results demonstrate the potential utility of our technology to rapidly discover unique protein signatures characteristic of various disease states.nnnCONCLUSIONS/SIGNIFICANCEnWe describe a versatile and powerful tool that allows large-scale comparison of proteome profiles among discrete populations. This unbiased and highly multiplexed search engine will enable the discovery of novel biomarkers in a manner that is unencumbered by our incomplete knowledge of biology, thereby helping to advance the next generation of evidence-based medicine.
PLOS ONE | 2011
Stephan Kraemer; Jonathan D. Vaught; Christopher Bock; Larry Gold; Evaldas Katilius; Tracy R. Keeney; Nancy D. Kim; Nicholas A. Saccomano; Sheri K. Wilcox; Dom Zichi; Glenn Sanders
Recently, we reported a SOMAmer-based, highly multiplexed assay for the purpose of biomarker identification. To enable seamless transition from highly multiplexed biomarker discovery assays to a format suitable and convenient for diagnostic and life-science applications, we developed a streamlined, plate-based version of the assay. The plate-based version of the assay is robust, sensitive (sub-picomolar), rapid, can be highly multiplexed (upwards of 60 analytes), and fully automated. We demonstrate that quantification by microarray-based hybridization, Luminex bead-based methods, and qPCR are each compatible with our platform, further expanding the breadth of proteomic applications for a wide user community.
Forensic Science International-genetics | 2018
Evaldas Katilius; Andrew B. Carmel; Heidi Koss; Dan O’Connell; Breanna C. Smith; Glenn Sanders; Greggory S. LaBerge
We have demonstrated a proof of concept with affinity-based purification of sperm cells from mock forensic samples using SOMAmer™ reagents, DNA-based affinity reagents developed by SomaLogic, Inc. SOMAmer reagents were selected in vitro using whole-cell SELEX to bind specifically with intact, detergent-treated sperm cells. Successful separation of sperm from epithelial cells and their debris was demonstrated using buccal swabs with added semen. Primarily male DNA profiles were generated from sperm cells eluted from the types of cotton swabs typically used for rape kit evidence collection. The quality of sperm DNA isolated from samples purified using SOMAmers is comparable to existing commercially available differential extraction-based methods at higher sperm concentrations. This purification method is simple, offers relatively rapid (<2hr) sperm purification, and can potentially be automated using robotic workstations. This work serves as proof of concept that demonstrates the first use of SOMAmer reagents as affinity ligands to bind sperm cells. With further development, this technique can potentially be used for high-throughput sexual assault forensic casework.
Clinical Cancer Research | 2010
Chris Bock; Evaldas Katilius; Tracy R. Keeney; Stephan Kraemer; Nick Saccomano; Glenn Sanders; Jonathan D. Vaught; Dom Zichi
To enable the application of protein signatures identified in our highly multiplexed biomarker discovery platform to real-world diagnostics, we developed a streamlined, plate-based assay that employs the same principles as the larger SOMAScan assay. The plate-based assay is sensitive (sub-picomolar), robust, rapid, automatable, and can multiplex upwards of 60 analytes. We have used this platform to seamlessly translate sets of biomarkers identified in our SOMAScan assay to a practical non-small cell lung cancer diagnostic.
Nature Precedings | 2010
Stephan Kraemer; Jonathon D. Vaught; Christopher Bock; Larry Gold; Evaldas Katilius; Tracy R. Keeney; Nancy D. Kim; Nicholas A. Saccomano; Sheri K. Wilcox; Dom Zichi; Glenn Sanders
Archive | 2013
Glenn Sanders; Stephan Kraemer; Evaldas Katilius
Archive | 2012
Glenn Sanders; Evaldas Katilius; Larry Gold
Archive | 2014
Urs Ochsner; Louis S. Green; Larry Gold; Nebojsa Janjic; Evaldas Katilius
Archive | 2017
Evaldas Katilius; Glenn Sanders; Stephan Kraemer
Archive | 2015
Glenn Sanders; Stephan Kraemer; Evaldas Katilius